This is the text extract for Proposal relating to four opthalmological products; Closing Date: Closed; Contact: Sue Anne Yee, browse documents here.

---

14 September 2011

Proposal relating to bimatoprost, brimonidine tartrate with timolol maleate and prednisolone acetate

PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Allergan Australia Pty Ltd for four ophthalmological products. In summary, this proposal would result in:  A reduction in the price and subsidy for bimatoprost (Lumigan) eye drops from 1 January 2012 with subsidy and delisting protection until 30 June 2015. A confidential rebate would apply. Subsidy and delisting protection for brimonidine tartrate with timolol maleate (Combigan) eye drops until 30 June 2015. A confidential rebate would apply. Subsidy and delisting protection for prednisolone acetate (Pred Mild and Pred Forte) until 30 June 2015.

 

Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Thursday, 29 September 2011 to:

Sue Anne Yee Therapeutic Group Manager PHARMAC PO Box 10 254 Wellington 6143

Email: sueanne.yee@pharmac.govt.nz Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal. Details of the proposal Bimatoprost (Lumigan)  The price and subsidy for Lumigan in Section B of the Pharmaceutical Schedule would be reduced from 1 January 2012 as follows (ex-manufacturer, exclusive of GST):

Chemical Bimatoprost

Presentation Eye drop 0.03%

Brand Lumigan

Pack size 3 ml OP

Current price and subsidy $19.50

Proposed price and subsidy from 1 Jan 2012 $18.50

A453177 Page 1 of 2

---

 

A confidential rebate would apply to Lumigan. Lumigan would have subsidy and delisting protection until 30 June 2015.

Brimonidine tartrate with timolol maleate (Combigan)  Combigan would remain fully funded in Section B of the Pharmaceutical Schedule at the current price and subsidy (ex-manufacturer, exclusive of GST):

Chemical Brimonidine tartrate with timolol maleate Presentation Eye drops 0.2% with timolol maleate 0.5% Brand Combigan Pack size 5 ml OP Price and subsidy

$18.50

 

A confidential rebate would apply to Combigan. Combigan would have subsidy and delisting protection until 30 June 2015.

Prednisolone acetate (Pred Mild and Pred Forte)  Pred Mild and Pred Forte would remain fully funded in Section B of the Pharmaceutical Schedule at the current prices and subsidies (ex-manufacturer, exclusive of GST):

Chemical Prednisolone acetate Prednisolone acetate Presentation Eye drops 0.12% Eye drops 1% Brand Pred Mild Pred Forte Pack size 5 ml OP 5 ml OP Price and subsidy $4.50 $4.50



Pred Mild and Pred Forte would have subsidy and delisting protection until 30 June 2015.

Background In response to PHARMAC’s consultation on the 2011/12 Invitation to Tender product list, Allergan Australia Pty Ltd submitted an alternative commercial proposal (ACP) involving bimatoprost, brimonidine tartrate with timolol maleate and prednisolone acetate eye drops. This ACP forms the basis of PHARMAC’s provisional agreement with Allergan and would result in Lumigan, Combigan, Pred Mild and Pred Forte remaining fully funded until at least 30 June 2015.

A453177

Page 2 of 2